Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PTPRC | P08575 | 2/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28354748 | 0.89 | SLC6A3 (0.35) | MTNR1AMTNR1BSLC6A3ALDH1A1 | |
| SCHEMBL28351117 | 0.86 | MGAM (0.37) | KDM4EALDH1A1EGFR | |
| SCHEMBL23639731 | 0.86 | EPHX2 (0.36) | MTNR1AMTNR1BCACNA1B | |
| SCHEMBL28351162 | 0.86 | MTNR1A (0.38) | MTNR1AMTNR1BSLC6A3KDM4EALDH1A1 | |
| SCHEMBL31507377 | 0.85 | MTOR (0.38) | MTNR1AMTNR1BCACNA1BKDM4EALDH1A1 | |
| SCHEMBL19296748 | 0.83 | ESR1 (0.33) | MTNR1AMTNR1BSLC6A3 | |
| SCHEMBL17434660 | 0.83 | ESR1 (0.34) | SLC6A3ALDH1A1 | |
| SCHEMBL29962699 | 0.83 | ESR1 (0.34) | SLC6A3ALDH1A1 | |
| SCHEMBL897783 | 0.79 | APP (0.41) | ALDH1A1 | |
| SCHEMBL29660078 | 0.79 | APP (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4321514-B1 | COMPOUND HAVING ALK INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | CGENETECH SUZHOU CHINA CO LTD (CN) | 2025-12-03 | — | — | EP | disclosed |
| EP-3848361-B1 | METHOD OF PRODUCING TETRACYCLIC COMPOUND | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-01-22 | — | — | EP | disclosed |
| US-20240246927-A1 | COMPOUNDS WITH ALK INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREOF | CGENETECH (SUZHOU, CHINA) CO., LTD. (CN) | 2024-07-25 | — | — | US | disclosed |
| CN-112585126-B | Process for preparing tetracyclic compounds | 中外制药株式会社 | 2024-05-07 | — | — | CN | disclosed |
| US-11939322-B2 | Method for producing tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-03-26 | — | — | US | disclosed |
| EP-4321514-A1 | COMPOUND HAVING ALK INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | CGeneTech (Suzhou, China) Co., Ltd. (CN) | 2024-02-14 | — | — | EP | disclosed |
| CN-115340523-B | Compound with ALK inhibitory activity and preparation method and application thereof | 盛世泰科生物医药技术(苏州)股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20220372025-A1 | METHOD FOR PRODUCING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-11-24 | — | — | US | disclosed |
| WO-2022237813-A1 | COMPOUND HAVING ALK INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | 盛世泰科生物医药技术(苏州)有限公司 | 2022-11-17 | — | — | WO | disclosed |
| US-9440922-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20160257667-A1 | SYNTHESIS OF INTERMEDIATES IN THE PREPARATION OF ALK INHIBITOR | XU YONG (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257667-A1 | SYNTHESIS OF INTERMEDIATES IN THE PREPARATION OF ALK INHIBITOR | XU YONG (US) | 2016-09-08 | — | — | US | disclosed |
| EP-2441753-B1 | TETRACYCLIC COMPOUND | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-03-30 | — | — | EP | disclosed |
| EP-2975024-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-9126931-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| CN-102459172-A | Tetracyclic compounds | CHUGAI PHARMACEUTICAL CO LTD | 2012-05-16 | — | — | CN | disclosed |
| EP-2441753-A1 | TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372025-A1 | METHOD FOR PRODUCING TETRACYCLIC COMPOUND | CYP1B1, CYP4B1, PAICS | MTNR1A 3238/4885MTNR1B 715/4885CACNA1B 161/4885 |
| US-20160257667-A1 | SYNTHESIS OF INTERMEDIATES IN THE PREPARATION OF ALK INHIBITOR | ALK, ACVR1B, ETV6 | MTNR1A 4879/4885MTNR1B 4736/4885CACNA1B 2212/4885 |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | MTNR1A 4200/4885MTNR1B 3833/4885CACNA1B 249/4885 |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | MTNR1A 4200/4885MTNR1B 3833/4885CACNA1B 249/4885 |
| US-20240246927-A1 | COMPOUNDS WITH ALK INHIBITORY ACTIVITY AND PREPARATION METHOD AND USE THEREOF | ALK, ACVR1, ALKBH3 | MTNR1A 4308/4885MTNR1B 3757/4885CACNA1B 2759/4885 |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | MTNR1A 4200/4885MTNR1B 3833/4885CACNA1B 249/4885 |
| US-11939322-B2 | Method for producing tetracyclic compound | CYP1B1, CYP4B1, PAICS | MTNR1A 3238/4885MTNR1B 715/4885CACNA1B 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.